www.tajpharma.com

BRUTRAX®
ANASTROZOLE
1mg TABLETS

BRUTRAX®
ANASTROZOLE
1mg TABLETS

Prescription BRUTRAX® is only for postmenopausal women. BRUTRAX® should not be taken if you are pregnant because it may harm your unborn child.
Do not take BRUTRAX® if you are allergic to any of its ingredients
Based on information from a study in patients with early breast cancer, women with a history of blockages in heart arteries (ischemic heart disease) who take BRUTRAX® may have a slight increase in this type of heart disease compared to similar patients who take tamoxifen
BRUTRAX® can cause bone softening/weakening (osteoporosis) increasing the chance of fractures. In a clinical study in early breast cancer, there were more fractures (including fractures of the spine, hip, and wrist) with BRUTRAX® (10%) than with tamoxifen (7%)
In a clinical study in early breast cancer, some patients taking BRUTRAX® had an increase in cholesterol. Skin reactions, allergic reactions, and changes in blood tests of liver function have also been reported
In the early breast cancer clinical trial, the most common side effects seen with BRUTRAX® include hot flashes, joint symptoms (including arthritis and arthralgia), weakness, mood changes, pain, back pain, sore throat, nausea and vomiting, rash, depression, high blood pressure, osteoporosis, fractures, swelling of arms/legs, insomnia, and headache

In advanced breast cancer trials, the most common side effects seen with BRUTRAX® versus tamoxifen include hot flashes, nausea, decreased energy and weakness, pain, back pain, headache, bone pain, increased cough, shortness of breath, sore throat, and swelling of arms and legs. Joint pain/stiffness has been reported in association with the use of BRUTRAX®

BRUTRAX® should not be taken with tamoxifen or estrogen-containing therapies
Approved Uses for BRUTRAX®

BRUTRAX® is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.

BRUTRAX® is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to BRUTRAX®.

Food and Drug Administration (FDA) approved .

A Taj Pharma”India Product